Holen Sie sich die Stockscreener-App
4.33
1.97%
-0.24
Schlusskurs vom Vortag:
$4.57
Offen:
$4.5
24-Stunden-Volumen:
21,285
Relative Volume:
0.12
Marktkapitalisierung:
$4.30M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-27.95M
KGV:
-0.0013
EPS:
-3331.1893
Netto-Cashflow:
$-26.12M
1W Leistung:
-30.00%
1M Leistung:
-33.23%
6M Leistung:
-83.07%
1J Leistung:
-99.48%
1-Tages-Spanne:
$4.27
$4.50
1-Wochen-Bereich:
$3.95
$6.735
52-Wochen-Spanne:
$3.95
$1,299.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.31 | 4.56M | 12.99M | -27.95M | -26.12M | -3,331.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.80 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.65 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Bitget
Leukemia trial: 86% of older patients benefit, no cytokine release syndrome - Stock Titan
Panic Selling: Is Aptevo Therapeutics Inc stock trending bullishQuarterly Investment Review & Daily Price Action Insights - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World
Retail Surge: Can Moodys Corporation reach resistance levels soon2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
APVO SEC FilingsAptevo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aptevo Therapeutics Inc expected to post a loss of $8.10 a shareEarnings Preview - TradingView
Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aptevo Therapeutics (APVO) sees Point72 report 0% ownership - Stock Titan
Seattle biotech CEO to step down, replacement named - The Business Journals
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest - Defense World
Will Aptevo Therapeutics Inc. stock remain a Wall Street favorite2025 Performance Recap & Long-Term Investment Growth Plans - mfd.ru
Will Aptevo Therapeutics Inc. be affected by tariffsCPI Data & AI Based Buy and Sell Signals - mfd.ru
Can Aptevo Therapeutics Inc. navigate macro headwindsJuly 2025 News Drivers & Technical Buy Zone Confirmation - mfd.ru
What is Aptevo Therapeutics Inc.’s valuation compared to sectorM&A Rumor & Accurate Entry/Exit Alerts - mfd.ru
Why Aptevo Therapeutics Inc. stock attracts high net worth investorsProduct Launch & Real-Time Market Sentiment Alerts - mfd.ru
Is Aptevo Therapeutics Inc. stock a value trapQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - mfd.ru
Aug Rallies: What is Aptevo Therapeutics Inc. s 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
Risk Report: Is Aptevo Therapeutics Inc impacted by rising ratesChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Is Aptevo Therapeutics Inc. stock a top momentum playSell Signal & Reliable Entry Point Alerts - mfd.ru
Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires By Investing.com - Investing.com Canada
Aptevo Announces CEO Changes - marketscreener.com
Aptevo Therapeutics Inc. Announces Board and Executive Changes - marketscreener.com
Aptevo Therapeutics Names Jeff Lamothe President and CEO as Marvin White Becomes Executive Chair - citybiz
Is Onto Innovation Inc stock risky to hold now2025 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Aptevo Therapeutics (APVO) Announces Changes in Leadership to Pr - GuruFocus
Aptevo Therapeutics IncMarvin White to retire as Aptevo CEO effective April 1, 2026SEC filing - marketscreener.com
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires - Investing.com
Aptevo (NASDAQ: APVO) elevates COO Jeff Lamothe to succeed CEO Marvin White - Stock Titan
Cancer drug developer Aptevo hands CEO role to operations chief - Stock Titan
Aptevo Therapeutics (APVO) Announces Offering of 7.075 Million S - GuruFocus
Aptevo Therapeutics prospectus relates to offer and sale of up to 7,075,471 shares of our common stock by selling stockholder - marketscreener.com
Aptevo Therapeutics Prospectus Relates To Offer And Sale Of Up To 7,075,471 Shares Of Our Common Stock By Selling Stockholder - TradingView
Aug Rallies: Is Aptevo Therapeutics Inc impacted by rising ratesJuly 2025 EndofMonth & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Growth Report: Can Compass Minerals International Inc. deliver consistent EPS growthInsider Selling & Community Verified Swing Trade Signals - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):